Buy or sell Pear Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Pear Therapeutics Stock

Pear discovers, develops, and commercializes Prescription Digital Therapeutics to treat diseases with high unmet need.




Boston MA, US

Total Funding


About Pear Therapeutics Stock

Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better efficacy for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead product, reSET®, is an FDA-cleared 12-week interval prescription digital therapeutic for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. Pear’s product development pipeline includes reSET-O® for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (Thrive), combat posttraumatic stress disorder (reCALL), general anxiety disorder (reVIVE), pain, major depressive disorder, and insomnia, for which Pear intends to obtain FDA clearance.

Funding History

March 2015$0
February 2016$20.0M
January 2018$50.0M
January 2019$64.0M


Chief Science Officer

Walter Greenleaf

Co-Founder & Executive Vice President of Corporate Development

Stephen Smith

Head of Advisory Board

Patrick Kennedy

Founder & CEO

Corey McCann

Co-Founder and Medical

William Greene

Chief Product and Content Officer

Beth Rogozinski

VP of Market Access, Reimbursement & Government Affairs

Everett Crosland

Vice President of Commercialization

Chris Lento

Vice President of Clinical Development

Yuri Maricich

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Pear Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: